Guided Therapeutics Inc Revenue Growth Rates (GTHP), Current and Historic Growth - CSIMarket
CSIMarket
 


Guided Therapeutics Inc   (GTHP)
 

GTHP's Revenue Growth by Quarter and Year

Guided Therapeutics Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GTHP/growth
https://api.csimarket.com/api/v1/companies/GTHP/fundamentals
https://api.csimarket.com/api/v1/companies/GTHP/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
GTHP Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.09
2nd Quarter June 0.00
1st Quarter March 0.00
FY 0.09

GTHPs Annual Revenue
Guided Therapeutics Inc 's Revenue in the fiscal year 2025 $ 0.77 millions
Guided Therapeutics Inc 's Revenue in the fiscal year 2024 $ 0.01 millions
Guided Therapeutics Inc 's Revenue in the fiscal year 2023 $ 0.10 millions
Guided Therapeutics Inc 's Revenue in the fiscal year 2022 $ 0.01 millions
Guided Therapeutics Inc 's Revenue in the fiscal year 2021 $ 0.08 millions




GTHP Revenue third quarter 2026 Y/Y Growth Comment
Guided Therapeutics Inc reported Revenue rise of 53.33% year on year in the third quarter 2026, to $ 0.09 millions, this is lower than Guided Therapeutics Inc 's recent average Revenue surge of 1364.53%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 27 other companies have achieved higher Revenue growth. While Guided Therapeutics Inc ' s Revenue jump of 53.33% ranks overall at the positon no. 475 in the third quarter 2026.




GTHP Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 53.33 %
2nd Quarter June -
1st Quarter March -
FY   -

Financial Statements
Guided Therapeutics Inc 's third quarter 2026 Revenue $ 0.09 millions GTHP's Income Statement
Guided Therapeutics Inc 's third quarter 2025 Revenue $ 0.06 millions Quarterly GTHP's Income Statement


GTHP Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March -
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #28
Healthcare Sector #119
Overall #475

Revenue Y/Y Growth Statistics
High Average Low
58900 % 1364.53 % -100 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #28
Healthcare Sector #119
Overall #475
Revenue Y/Y Growth Statistics
High Average Low
58900 % 1364.53 % -100 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Guided Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GTHP's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GTHP's III. Quarter Q/Q Revenue Comment


Guided Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)
12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
In the Sep 30 2026 period, Guided Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Guided Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Sep 30 2026 period, Guided Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Guided Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GTHP's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Kyntra Bio Inc 63.75%$ 63.755 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Fennec Pharmaceuticals Inc 57.34%$ 57.342 millions


About Guided Therapeutics Inc Revenue Growth Rates (GTHP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Guided Therapeutics Inc (CIK 924515).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001477932-26-007012
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Guided Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.